CD47 illustration: Shutterstock
Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal
Earlier this summer, a small biotech company’s readout in what was once one of cancer’s most intriguing approaches did little to settle the controversy and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
